Reshaping the HIV treatment and prevention landscape
Delivering high potential specialty medicines and strong commercial execution gsk
Infectious diseases
Industry leader with
broadest infectious
diseases pipeline
HIV
Reshaping the
HIV treatment and
prevention landscape
Oncology
Next-gen IO and synthetic
lethality leadership
Immunology/
Respiratory
Industry leader in
genetically validated
immune driven targets
Opportunity
driven
Create future therapy
areas of focus
gepotidacin
UUTI/GC
HBV ASO '836
Hepatitis B
Cabenuva
Cab PrEP
Blenrep
Multiple myeloma
Jemperli*
1L endometrial
Zejula
Ovarian, lung, breast
With many further opportunities to contribute to long term growth
Nucala
COPD
Linerixibat
CP in PBC
'254 mat inhib
HIV
'608 CD96
Cancer
Vir-7831
COVID-19
cobolimab*
NSCLC
EOS-448^
Cancer
'279 CCL17
OA pain
Vir-7832
COVID-19
*393 TG2
Celiac disease
depemokimab ('294)
Asthma
otilimab
RA
daprodustat
Anaemia w CKD
NY-ESO-1 TCR's
Cancer
'109/N6LS bNAb
HIV
'676 MAT2A
Cancer
'347 FimH
UUTI
'868 PI4Kẞ
Viral COPD
exacerbations
'417 STING
Cancer
'745 TRPV4
DME
Pipeline is not exhaustive and does not include Vaccines
CP in PBC cholestatic pruritus in PBC; RA rheumatoid arthritis; uUTI uncomplicated urinary tract infection; GC gonorrhoea; NSCLC non-small cell lung cancer; OA osteoarthritis; CKD chronic kidney disease
*Tesaro asset,^iTeos Therapeutics collaboration subject to regulatory clearance
'595 PRMT5
Cancer
84View entire presentation